Summary & Overview
HCPCS Level II J0652: Levothyroxine Sodium Injection, 10 mcg
HCPCS Level II code J0652 denotes a 10 mcg injection of levothyroxine sodium (Hikma), specified as not therapeutically equivalent to J0650. As an injectable formulation of thyroid hormone replacement, this code captures a relatively specialized administration event performed in outpatient settings such as physician offices or infusion centers. Nationally, accurate coding drives appropriate claim processing for therapy that supports patients with hypothyroidism or other conditions requiring parenteral thyroid hormone.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise view of reimbursement benchmarks, clinical context for injectable levothyroxine use, and coding guidance relevant to facility and professional billing lines. Readers will find practical information on service description, typical sites of service, payer coverage considerations, and where to look for related coding entries.
This summary is intended as a national reference for billing and policy teams, practice managers, and clinicians who need a clear explanation of what J0652 represents, how it differs from similar HCPCS Level II entries, and the operational contexts in which this code is used.
Billing Code Overview
HCPCS Level II code J0652 describes an injection of levothyroxine sodium (Hikma), not therapeutically equivalent to J0650, 10 mcg. This entry represents a physician-administered thyroid hormone replacement delivered as a parenteral injectable formulation.
Service type: Therapeutic injection (endocrine replacement therapy)
Typical site of service: Outpatient clinics, physician office, or infusion/administration centers
Clinical & Coding Specifications
Clinical Context
A 52-year-old female with a history of primary hypothyroidism presents to an outpatient infusion clinic after inability to tolerate orally administered levothyroxine due to prolonged ileus following abdominal surgery. The endocrinologist orders parenteral levothyroxine sodium, J0652, 10 mcg, to be administered intramuscularly while the patient is NPO and absorption of oral formulations is unreliable. The clinical workflow includes verification of the medication order, allergy and double-check by pharmacy, dose preparation by the licensed pharmacist or pharmacy technician under supervision, and administration by a registered nurse. Vital signs are obtained before and after injection; the nurse documents site, lot number, dose, and patient response. Subsequent endocrine follow-up includes monitoring thyroid function tests (TSH, free T4) and transition planning back to oral therapy when clinically appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Default; no special circumstances apply to the service |
22 | Increased procedural services |